Form 4: Vaxcyte CFO Exercises Stock Options, Reports Beneficial Ownership

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., reports exercising stock options and subsequent beneficial ownership of securities.

Summary

• On April 7, 2025, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc. (PCVX), executed a transaction involving stock options.
• He exercised options to acquire 4,777 shares of common stock at a price of $20.93 per share.
• Following this transaction, Guggenhime directly owns 131,950 shares of Vaxcyte common stock.
• He also holds options for 121,115 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document is a standard regulatory filing detailing stock option exercises. While insider transactions can be interpreted as a sign of confidence, this is a routine disclosure.

Positives

• The exercise of stock options by a high-ranking executive can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment of interests.

Stakeholder Impact

• Shareholders can use this information to assess the alignment of management's interests with their own.

Key Dates

Keywords

Vaxcyte, Guggenhime, stock options, beneficial ownership, Form 4, PCVX, CFO